Celcuity's (CELC) Buy Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of Celcuity (NASDAQ:CELC - Free Report) in a research report released on Friday morning,Benzinga reports. They currently have a $23.00 target price on the stock.

Other research analysts have also issued reports about the company. Stifel Nicolaus raised their price objective on Celcuity from $39.00 to $42.00 and gave the company a "buy" rating in a research report on Monday, October 7th. Leerink Partners assumed coverage on Celcuity in a research note on Monday, July 22nd. They set an "outperform" rating and a $29.00 price target for the company. HC Wainwright reaffirmed a "buy" rating and issued a $27.00 price target on shares of Celcuity in a research report on Thursday, August 15th. Lifesci Capital initiated coverage on shares of Celcuity in a research note on Monday, August 26th. They set an "outperform" rating and a $27.00 price target on the stock. Finally, Leerink Partnrs upgraded shares of Celcuity to a "strong-buy" rating in a research report on Monday, July 22nd. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $29.17.

Celcuity Trading Down 10.3 %

Shares of Celcuity stock traded down $1.45 during trading on Friday, hitting $12.66. The stock had a trading volume of 954,216 shares, compared to its average volume of 279,872. Celcuity has a 12 month low of $11.51 and a 12 month high of $22.19. The stock has a market cap of $468.80 million, a PE ratio of -4.68 and a beta of 0.76. The firm's fifty day simple moving average is $15.23 and its 200-day simple moving average is $16.07. The company has a debt-to-equity ratio of 0.54, a current ratio of 14.95 and a quick ratio of 14.95.

Celcuity (NASDAQ:CELC - Get Free Report) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.62) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.71) by $0.09. During the same quarter in the previous year, the business earned ($0.66) EPS. As a group, sell-side analysts expect that Celcuity will post -2.54 EPS for the current fiscal year.

Institutional Trading of Celcuity

Institutional investors have recently added to or reduced their stakes in the stock. Samlyn Capital LLC grew its position in Celcuity by 92.4% during the second quarter. Samlyn Capital LLC now owns 1,326,953 shares of the company's stock valued at $21,735,000 after buying an additional 637,190 shares during the period. Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in shares of Celcuity in the first quarter worth $3,545,000. Driehaus Capital Management LLC raised its position in Celcuity by 62.3% in the 2nd quarter. Driehaus Capital Management LLC now owns 204,592 shares of the company's stock worth $3,351,000 after purchasing an additional 78,525 shares during the period. Blue Owl Capital Holdings LP bought a new position in Celcuity in the 2nd quarter valued at $1,065,000. Finally, Hennion & Walsh Asset Management Inc. purchased a new position in shares of Celcuity in the 2nd quarter valued at $888,000. 63.33% of the stock is currently owned by institutional investors.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.